We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Haleon Plc | LSE:HLN | London | Ordinary Share | GB00BMX86B70 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 2.90 | 0.87% | 334.40 | 24,166,169 | 16:35:01 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 334.70 | 334.80 | 336.00 | 330.80 | 332.70 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 11.3B | 1.05B | 0.1136 | 29.47 | 30.92B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 18:53:50 | O | 90,827 | 332.378 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 24/4/2024 | 09:15 | ALNC |  Haleon appoints Tate & Lyle's finance chief as CFO from November |
| 24/4/2024 | 07:00 | UK RNS | Haleon PLC Appointment of Dawn Allen as CFO |
| 12/4/2024 | 12:00 | UK RNS | Haleon PLC Notice of Annual General Meeting (AGM) |
| 03/4/2024 | 11:30 | UK RNS | Haleon PLC Director/PDMR Shareholding |
| 02/4/2024 | 09:15 | UK RNS | Haleon PLC Total Voting Rights and Capital |
| 22/3/2024 | 11:30 | UK RNS | Haleon PLC Holding(s) in Company |
| 21/3/2024 | 18:00 | UK RNS | FTSE Russell Haleon |
| 21/3/2024 | 16:38 | UK RNS | Haleon PLC Total Voting Rights and Capital |
| 21/3/2024 | 16:29 | ALNC | TOP NEWS: Haleon buys back shares worth GBP315 million from Pfizer |
| 21/3/2024 | 16:05 | UK RNS | Haleon PLC Closing of Secondary Global Offering by Pfizer |
Haleon (HLN) Share Charts1 Year Haleon Chart |
|
1 Month Haleon Chart |
Intraday Haleon Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-26 17:54:16 | 332.38 | 90,827 | 301,888.97 | O |
| 2024-04-26 17:53:05 | 331.23 | 1,270 | 4,206.57 | O |
| 2024-04-26 17:53:05 | 332.85 | 15,144 | 50,406.05 | O |
| 2024-04-26 17:45:02 | 333.47 | 15 | 50.02 | O |
| 2024-04-26 17:45:02 | 332.67 | 1,894 | 6,300.81 | O |
| Top Posts |
|---|
Posted at 27/4/2024 09:20 by Haleon Daily Update Haleon Plc is listed in the Offices-holdng Companies,nec sector of the London Stock Exchange with ticker HLN. The last closing price for Haleon was 331.50p.Haleon currently has 9,234,573,831 shares in issue. The market capitalisation of Haleon is £30,917,353,186. Haleon has a price to earnings ratio (PE ratio) of 29.47. This morning HLN shares opened at 332.70p |
Posted at 18/4/2024 11:25 by philanderer HSBC starts Haleon with 'buy' - price target 370 pence |
Posted at 19/3/2024 10:11 by alphorn Not forgetting that a takeover is made easier if a large holder agrees to sell in advance to an acquirer. HLN IMO will get acquired at some point. |
Posted at 18/3/2024 11:49 by alphorn Pfizer to cut stake in HLN - see above. |
Posted at 25/1/2024 07:44 by simon8 Bon voyage Chapstick, looks like a good deal, cash, pay down debt and a passive forward interest. Let's hope we see an uptick in the share price, we need it! |
Posted at 17/1/2024 23:11 by pdosullivan Another very welcome placing by GSK, which has now sold down two thirds of the shares it originally held post IPO. Given the cash HLN is throwing off and reports that it might sell one of its brands for up to USD800m I wonder if the company might bid GSK for some or all of its remaining stock later this year. |
Posted at 17/1/2024 10:55 by zho GSK plc (LSE/NYSE: GSK) today announced that, further to its announcement on 16 January 2024, GSK has agreed to sell 300m ordinary shares in Haleon plc ("Haleon") at a price of 326 pence per share (the "Placing Shares"), raising gross proceeds of approximately GBP978m (the "Placing").Following settlement of the Placing, GSK will hold approximately 385m ordinary shares in Haleon, representing approximately 4.2% of the issued share capital of Haleon. |
Posted at 15/12/2023 13:45 by anhar Trailing yield is actually 1.3%. This is based on last 12m divis total 4.2p (22 final of 2.4p plus 23 interim 1.8p) on the share price of 319p. The 23 forecast is for 5.5p making a forward yield of 1.7%.Still very low though. I hold HLN acquired via the GSK demerger and what may be supporting the price, if you think there is a reason other than the normal random walk of share prices, is bid hopes, as you suggest. Everyone thinks that, making it less likely! |
Posted at 14/12/2023 18:57 by alphorn Still don't understand what is holding up this share price P/e close to 20 and a yield below 1% makes little sense for this sector.I expect the company to be taken out but at what price? Patient, you have holdings here. Do you have any answers; it just seems unsupportable? |
Posted at 12/10/2022 04:55 by paul planet earth 'Wallet Investor’s Haleon long-term forecast indicated that the stock could be a non-viable investment. The algorithm-based forecasting service predicted that the share price could fall to £2.21 by the end of 2022 and decline throughout 2023 to trade at just £0.09 by the end of the year. The stock could effectively fall to zero by 2024, according to WalletInvestor&rsquoThe Haleon stock 5-year forecast from Gov Capital similarly estimated that the American Depositary Receipts (ADRs) for Haleon listed in the US could drop to zero, but by November 2023.' The most likely scenario is that due to the impact of generic drug labels, rising consumer inflation, and multi billion dollar Zantac litigation costs and settlements the share price will fall. The high burden of existing debt, rising interest rates, and flattening consumer sales reflected in the falling share price, note the price is down 16% since floatation with the expected off loading of both Pfizer and GSK's share holdings in November places more downward pressure on the share price on the foreseeable future. |
Posted at 07/10/2022 10:31 by anhar Strange how the share has been rising in recent weeks, given that the lock-in overhang from GSK and PFE is public knowledge and has been ever since the demerger details were released months ago.I don't have the faintest idea of the manner in which they might dispose of their HLN shares and how it might affect the share price, but it just seems odd that if you are correct with your repetitive assertions about a price crash driven by big sales, why would the price be rising now? Big cap share prices are driven by institutional trading, small private investors like us are irrelevant. So the rising price must be driven by inst buying on balance. Why would that be if it is feared that the price would soon collapse? Surely, if your view proves anywhere near accurate, they would be better waiting for the big HLN price crash you keep mentioning. In other words their opinions must be virtually the exact opposite of yours. I''m not saying that insts are always right, they're often wrong, but it does appear odd in this situation where there's only a few weeks at stake. My view is that any potential big price fall is already in the price so there is little to fear. In any case, personally I hold shares very long term so I'm hanging on to my HLN allocation as it may prove to be a good share in years to come. Short term fears like you keep stating are of no concern to me and even if you're right, I'd see it as a buying opportunity and nothing to worry about. Nobody is going to care in several years time about a historical GSK/PFE overhang. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
